APA (7th ed.) Citation

S, K., T, F., J, I., A, K., T, T., N, M., . . . S, U. (2023). Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: An observational study. BMC nephrology, 24(1), 12. https://doi.org/10.1186/s12882-023-03060-1

Chicago Style (17th ed.) Citation

S, Kameda, Fujii T, Ikeda J, Kageyama A, Takagi T, Miyayama N, Asano K, Endo A, and Uezono S. "Unfractionated Heparin Versus Nafamostat Mesylate for Anticoagulation During Continuous Kidney Replacement Therapy: An Observational Study." BMC Nephrology 24, no. 1 (2023): 12. https://doi.org/10.1186/s12882-023-03060-1.

MLA (9th ed.) Citation

S, Kameda, et al. "Unfractionated Heparin Versus Nafamostat Mesylate for Anticoagulation During Continuous Kidney Replacement Therapy: An Observational Study." BMC Nephrology, vol. 24, no. 1, 2023, p. 12, https://doi.org/10.1186/s12882-023-03060-1.